Synmosa Biopharma (TWO:4114) — Stock Price

NT$29.50 TWD
▲ 0.85% today

Synmosa Biopharma (TWO:4114) is currently trading at NT$29.50 TWD, up 0.85% today. Over the past 52 weeks, shares have ranged between NT$28.90 and NT$37.50. This page tracks Synmosa Biopharma's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 4114 company net worth.

Synmosa Biopharma (4114) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Synmosa Biopharma's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.

Synmosa Biopharma Income Statement — Revenue, Profit & Earnings by Year

Synmosa Biopharma's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue NT$6.19 Billion NT$5.55 Billion NT$5.14 Billion NT$4.39 Billion NT$3.23 Billion
Cost of Revenue NT$3.51 Billion NT$3.15 Billion NT$3.02 Billion NT$2.56 Billion NT$1.95 Billion
Gross Profit NT$2.68 Billion NT$2.40 Billion NT$2.12 Billion NT$1.83 Billion NT$1.29 Billion
Research & Development NT$342.67 Million NT$259.72 Million NT$210.91 Million NT$215.28 Million NT$214.37 Million
SG&A NT$1.56 Billion NT$1.40 Billion NT$1.29 Billion NT$1.15 Billion NT$883.58 Million
Total Operating Expenses NT$5.41 Billion NT$4.81 Billion NT$4.52 Billion NT$3.93 Billion NT$3.05 Billion
Operating Income NT$777.94 Million NT$739.08 Million NT$620.34 Million NT$455.02 Million NT$185.20 Million
EBITDA NT$1.10 Billion NT$507.92 Million
EBIT NT$186.74 Million
Interest Expense NT$62.06 Million NT$58.10 Million NT$67.26 Million NT$59.58 Million NT$51.97 Million
Income Before Tax NT$799.64 Million NT$659.07 Million NT$601.56 Million NT$725.01 Million NT$153.89 Million
Income Tax Expense NT$37.81 Million
Net Income NT$821.85 Million NT$684.68 Million NT$594.83 Million NT$799.09 Million NT$303.86 Million

Synmosa Biopharma Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Synmosa Biopharma's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets NT$13.99 Billion NT$12.30 Billion NT$11.73 Billion NT$11.20 Billion NT$10.32 Billion
Total Current Assets NT$6.67 Billion NT$5.02 Billion NT$4.54 Billion NT$4.01 Billion NT$3.10 Billion
Cash & Equivalents
Short-term Investments NT$1.04 Billion NT$699.34 Million NT$736.33 Million NT$331.68 Million NT$124.96 Million
Net Receivables NT$1.29 Billion NT$1.16 Billion NT$1.28 Billion NT$1.28 Billion NT$923.66 Million
Inventory NT$2.19 Billion NT$1.71 Billion NT$1.60 Billion NT$1.30 Billion NT$1.17 Billion
Property, Plant & Equipment NT$5.66 Billion
Goodwill NT$50.26 Million NT$62.29 Million NT$62.29 Million NT$71.08 Million NT$7.27 Million
Total Liabilities NT$3.89 Billion NT$3.91 Billion NT$3.63 Billion NT$4.55 Billion NT$4.22 Billion
Total Current Liabilities NT$2.26 Billion NT$2.07 Billion NT$2.12 Billion NT$2.32 Billion NT$1.89 Billion
Long-term Debt NT$1.54 Billion NT$1.73 Billion NT$1.40 Billion NT$2.12 Billion NT$2.27 Billion
Net Debt NT$565.53 Million NT$1.29 Billion NT$1.52 Billion NT$2.28 Billion NT$2.60 Billion
Total Stockholder Equity NT$8.76 Billion NT$7.21 Billion NT$6.71 Billion NT$5.31 Billion NT$4.71 Billion
Retained Earnings NT$899.07 Million NT$722.32 Million NT$813.91 Million NT$812.68 Million NT$441.79 Million

Synmosa Biopharma Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Synmosa Biopharma generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow NT$411.57 Million NT$780.62 Million NT$511.93 Million NT$630.25 Million NT$444.29 Million
Capital Expenditures NT$281.13 Million NT$269.65 Million NT$269.77 Million NT$129.29 Million NT$93.06 Million
Free Cash Flow NT$130.44 Million NT$510.97 Million NT$242.16 Million NT$445.92 Million NT$302.17 Million
Investing Cash Flow NT$-69.33 Million NT$83.90 Million
Financing Cash Flow NT$-297.57 Million
Dividends Paid NT$272.61 Million NT$228.74 Million NT$194.43 Million NT$148.63 Million NT$79.98 Million
Stock-Based Compensation NT$35.87 Million NT$14.64 Million NT$17.21 Million NT$22.47 Million NT$10.63 Million
Depreciation NT$343.20 Million NT$341.97 Million NT$339.92 Million NT$315.64 Million NT$297.29 Million
Change in Cash NT$705.14 Million NT$267.55 Million NT$-169.09 Million NT$219.48 Million NT$229.82 Million

Synmosa Biopharma Earnings History — EPS Actual vs. Analyst Estimates

Track Synmosa Biopharma's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Nov 14, 2025 0.41 0.62 -33.87%
Aug 13, 2025 0.43 0.58 -25.86%
Apr 29, 2025 0.29 0.52 -44.23%
Mar 28, 2025 0.33 0.57 -42.11%
Nov 12, 2024 0.35 0.51 -31.37%
May 15, 2024 0.37 0.39 -5.13%
Mar 29, 2024 0.44 0.43 +2.97%
Nov 12, 2023 0.29 0.39 -25.64%